| Full text | |
| Author(s): |
Negri, C. E.
[1]
;
Goncalves, S. S.
[1]
;
Xafranski, H.
[1]
;
Bergamasco, M. D.
[1]
;
Aquino, V. R.
[2]
;
Castro, P. T. O.
[3]
;
Colombo, A. L.
[1]
Total Authors: 7
|
| Affiliation: | [1] Univ Fed Sao Paulo, Escola Paulista Med, Div Infect Dis, Sao Paulo - Brazil
[2] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS - Brazil
[3] Hosp Canc Barretos, Barretos, SP - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | Journal of Clinical Microbiology; v. 52, n. 10, p. 3633-3640, OCT 2014. |
| Web of Science Citations: | 32 |
| Abstract | |
Aspergillus spp. are among the most common causes of opportunistic invasive fungal infections in tertiary care hospitals. Little is known about the prevalence and in vitro susceptibility of Aspergillus species in Latin America, because there are few medical centers able to perform accurate identification at the species level. The purpose of this study was to analyze the distribution of cryptic and rare Aspergillus species among clinical samples from 133 patients with suspected aspergillosis admitted in 12 medical centers in Brazil and to analyze the in vitro activity of different antifungal drugs. The identification of Aspergillus species was performed based on a polyphasic approach, as well as sequencing analysis of the internal transcribed spacer (ITS) region, calmodulin, and beta-tubulin genes and phylogenetic analysis when necessary. The in vitro susceptibility tests with voriconazole, posaconazole, and itraconazole were performed according to the CLSI M38-A2 document (2008). We demonstrated a high prevalence of cryptic species causing human infection. Only three isolates, representing the species Aspergillus thermomutatus, A. ochraceus, and A. calidoustus, showed less in vitro susceptibility to at least one of the triazoles tested. Accurate identifications of Aspergillus at the species level and with in vitro susceptibility tests are important because some species may present unique resistance patterns against specific antifungal drugs. (AU) | |
| FAPESP's process: | 12/19103-1 - Evaluation of the anti-tumour and angiogenic activity of the Aspergillus fumigatus secretome |
| Grantee: | Hemílio Xafranski |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 12/01134-8 - Prevalence of Aspergillus species in samples from clinical/environmental origin and analysis of their susceptibility profile to six antifungals |
| Grantee: | Arnaldo Lopes Colombo |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 12/01548-7 - Prevalence of Aspergillus species from clinical/environmental samples and analyze of its susceptibility profile to six antifungal |
| Grantee: | Clara Ezequiel Negri |
| Support Opportunities: | Scholarships in Brazil - Master |